MEDIROM Surpasses Milestone with ‘Lav’ Health App

MEDIROM Healthcare Technologies ( (MRM) ) has issued an announcement.

On May 30, 2025, MEDIROM Healthcare Technologies Inc. announced that its subsidiary, MEDIROM MOTHER Labs Inc., has surpassed 100 cumulative contracted companies and 10,000 cumulative supported individuals with its specific health guidance service using the ‘Lav’ healthcare app. This service, initiated in 2019, aims to prevent lifestyle-related diseases and promote health management by utilizing information and communication technology. The achievement highlights the company’s commitment to improving service quality and strengthening its support system, positioning it as a significant player in the healthcare industry.

The most recent analyst rating on (MRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.

Spark’s Take on MRM Stock

According to Spark, TipRanks’ AI Analyst, MRM is a Neutral.

MEDIROM Healthcare Technologies demonstrates a mix of growth and risk. Strong revenue growth is a positive, but profitability and cash flow challenges, alongside high leverage, pose significant risks. The technical analysis suggests short-term positive momentum, though overbought signals could lead to a correction. The valuation appears favorable with a low P/E ratio, adding investment appeal.

To see Spark’s full report on MRM stock, click here.

More about MEDIROM Healthcare Technologies

MEDIROM Healthcare Technologies Inc. is a holistic healthcare company based in Japan, operating over 300 wellness salons with its leading brand Re.Ra.Ku®. The company entered the health tech business in 2015, launching the ‘Lav®’ app, and expanded into the device business in 2020 with the ‘MOTHER Bracelet®’. In 2023, it introduced REMONY, a remote monitoring system for corporate clients across various industries.

Average Trading Volume: 1,860,711

Technical Sentiment Signal: Hold

Current Market Cap: $11.48M

Learn more about MRM stock on TipRanks’ Stock Analysis page.